Opinion|Videos|March 11, 2024

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults (D-ALBA)

Author(s)Ashwin Kishtagari, MD, Vivek Govind Patel, MD, Nisha Joseph, MD

Experts discuss the Phase 2 D-ALBA trial results examining combination of dasatinib plus blinatumomab as frontline therapy for adults with Philadelphia chromosome-positive B cell acute lymphoblastic leukemia.

Episodes in this series

EP. 1 Multiple Myeloma and ALL Experts Face Off in Data Analyzing Cilta-Cel and Ponatinib Hydrochloride

EP. 1 Multiple Myeloma and ALL Experts Face Off in Data Analyzing Cilta-Cel and Ponatinib Hydrochloride

EP. 2 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

EP. 2 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

EP. 3 Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From ECOG-ACRIN E1910

EP. 3 Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From ECOG-ACRIN E1910

EP. 4 Frontline Combination of Ponatinib and Hyper-CVAD in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 80-Months Follow-up Results

EP. 4 Frontline Combination of Ponatinib and Hyper-CVAD in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 80-Months Follow-up Results

EP. 5 Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults (D-ALBA)

EP. 5 Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults (D-ALBA)

EP. 6 Cancer Network Faceoff: Conclusion of the Event and Presentation of Award

EP. 6 Cancer Network Faceoff: Conclusion of the Event and Presentation of Award

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Acute Myeloid Leukemia | Image Credit: © LASZLO - stock.adobe.com.

November 6th, 2026

Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML

Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.

Trending on CancerNetwork

Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC

Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC

FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors

Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC

Top 3 Poster Takeaways in Liver Cancer Care From The Liver Meeting 2026